Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3HP for TB prevention in children with HIV on dolutegravir
NCT05122767Phase 2Active, not recruiting
- Sponsor
- Aurum Institute
- Start
- May 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of rifapentine, isoniazid and dolutegravir in latent tuberculosis infection (LTBI), sponsored by Aurum Institute. Started May 2023; status: active, not recruiting.
02
Drugs
rifapentineisoniaziddolutegravir
03
Conditions
latent tuberculosis infection (LTBI)
Beyond the preview
Go deeper on NCT05122767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05122767.